免疫检查点抑制剂引发放射唤醒性肺炎的研究进展

doi:10.3760/cma.j.cn371439-20220516-00114

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (10): 577-580.doi: 10.3760/cma.j.cn371439-20220516-00114

• 一切为了人民健康——我们这十年 • 下一篇

免疫检查点抑制剂引发放射唤醒性肺炎的研究进展

张杰^1,², 魏渼倬², 赵玲², 易善永²()

¹新乡医学院研究生院，新乡 453003
²郑州大学附属郑州中心医院肿瘤内科，郑州 450007

收稿日期:2022-05-16 修回日期:2022-06-06 出版日期:2022-10-08 发布日期:2022-12-01
通讯作者: 易善永 E-mail:yisy2001@126.com
基金资助:
吴阶平医学基金会临床科研专项资助基金(320.6750.2021-02-142)

Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors

Zhang Jie^1,², Wei Meizhuo², Zhao ling², Yi Shanyong²()

¹Graduate School of Xinxiang Medical University， Xinxiang 453003， China
²Department of Oncology， Zhengzhou Central Hospital Affiliated to Zhengzhou University， Zhengzhou 450007， China

Received:2022-05-16 Revised:2022-06-06 Online:2022-10-08 Published:2022-12-01
Contact: Yi Shanyong E-mail:yisy2001@126.com
Supported by:
Wu Jieping Medical Foundation Clinical Scientific Research Special Fund(320.6750.2021-02-142)

摘要/Abstract

摘要：

目前肿瘤治疗进入了免疫治疗时代。但近年来发现，胸部放疗后应用免疫检查点抑制剂在起到协同抗肿瘤作用的同时，也会引发放射唤醒性肺炎（RRP）。RRP是一种少见的免疫相关不良反应，严重者甚至导致患者死亡。研究免疫检查点抑制剂引起RRP的相关机制以及影响因素，对加强RRP的认知管理以及降低RRP发生风险具有重要意义。

关键词: 免疫检查点抑制剂, 免疫疗法, 放射疗法, 肺炎, 辐射性肺炎

Abstract:

At present， tumor therapy has entered the era of immunotherapy. However， in recent years， it has been found that the application of immune checkpoint inhibitors after chest radiotherapy can not only play a synergistic anti-tumor effect， but also cause radiation recall pneumonitis （RRP）. RRP is a rare immune-related adverse reaction， which even leads to death in severe cases. It is of great significance to study the mechanisms and influencing factors of RRP caused by immune checkpoint inhibitors for strengthening the cognitive management of RRP and reducing the risk of RRP.

Key words: Immune checkpoint inhibitors, Immunotherapy, Radiotherapy, Pneumonia, Radiation pneumonitis

张杰, 魏渼倬, 赵玲, 易善永. 免疫检查点抑制剂引发放射唤醒性肺炎的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 577-580.

Zhang Jie, Wei Meizhuo, Zhao ling, Yi Shanyong. Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors[J]. Journal of International Oncology, 2022, 49(10): 577-580.

参考文献 31

[1]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108. doi: 10.1097/CM9.0000000000002108
[2]	Laird J, Leventhal J, Kanowitz J, et al. Radiation recall dermatitis after capecitabine in a patient with triple negative breast cancer[J]. Pract Radiat Oncol, 2021, 11(6): 448-452. DOI: 10.1016/j.prro.2021.06.001. doi: 10.1016/j.prro.2021.06.001
[3]	Ye X, Yang J, Stebbing J, et al. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report[J]. BMC Pulm Med, 2022, 22(1): 54. DOI: 10.1186/s12890-022-01846-x. doi: 10.1186/s12890-022-01846-x pmid: 35123465
[4]	McKay MJ, Foster R. Radiation recall reactions: an oncologic enigma[J]. Crit Rev Oncol Hematol, 2021, 168: 103527. DOI: 10.1016/j.critrevonc.2021.103527. doi: 10.1016/j.critrevonc.2021.103527
[5]	McGovern K, Ghaly M, Esposito M, et al. Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review[J]. Future Sci OA, 2019, 5(5): FSO378. DOI: 10.2144/fsoa-2018-0123. doi: 10.2144/fsoa-2018-0123
[6]	Cousin F, Desir C, Ben Mustapha S, et al. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer[J]. Radiother Oncol, 2021, 157: 47-55. DOI: 10.1016/j.radonc.2021.01.001. doi: 10.1016/j.radonc.2021.01.001 pmid: 33453313
[7]	Wang YY, Tian XC, Zhu L, et al. Concomitant radiation recall der-matitis and radiation recall pneumonitis induced by pembrolizumab[J]. J Thorac Oncol, 2020, 15(10): e160-e162. DOI: 10.1016/j.jtho.2020.05.014. doi: 10.1016/j.jtho.2020.05.014
[8]	Chen Y, Huang Z, Xing L, et al. Radiation recall pneumonitis induced by anti-PD-1 blockade: a case report and review of the literature[J]. Front Oncol, 2020, 10: 561. DOI: 10.3389/fonc.2020.00561. doi: 10.3389/fonc.2020.00561 pmid: 32411597
[9]	Giuranno L, Ient J, De Ruysscher D, et al. Radiation-induced lung injury (RILI)[J]. Front Oncol, 2019, 9: 877. DOI: 10.1186/s12890-020-01376-4. doi: 10.3389/fonc.2019.00877 pmid: 31555602
[10]	Guo L, Ding G, Xu W, et al. Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging[J]. Exp Ther Med, 2019, 17(1): 244-250. DOI: 10.3892/etm.2018.6936. doi: 10.3892/etm.2018.6936 pmid: 30651789
[11]	Zhang Z, Zhou J, Verma V, et al. Crossed pathways for radiation-induced and immunotherapy-related lung injury[J]. Front Immunol, 2021, 12: 774807. DOI: 10.3389/fimmu.2021.774807. doi: 10.3389/fimmu.2021.774807
[12]	Jia XH, Geng LY, Jiang PP, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors[J]. J Exp Clin Cancer Res, 2020, 39(1): 284. DOI: 10.1186/s13046-020-01749-x. doi: 10.1186/s13046-020-01749-x
[13]	Lu L, Sun C, Su Q, et al. Radiation-induced lung injury: latest molecular developments, therapeutic approaches, and clinical guidance[J]. Clin Exp Med, 2019, 19(4): 417-426. DOI: 10.1007/s10238-019-00571-w. doi: 10.1007/s10238-019-00571-w pmid: 31313081
[14]	Ullah T, Patel H, Pena GM, et al. A contemporary review of radiation pneumonitis[J]. Curr Opin Pulm Med, 2020, 26(4): 321-325. DOI: 10.1097/MCP.0000000000000682. doi: 10.1097/MCP.0000000000000682 pmid: 32427626
[15]	Roy S, Salerno KE, Citrin DE. Biology of radiation-induced lung injury[J]. Semin Radiat Oncol, 2021, 31(2): 155-161. DOI: 10.1016/j.semradonc.2020.11.006. doi: 10.1016/j.semradonc.2020.11.006 pmid: 33610273
[16]	Bukamur H, Katz H, Alsharedi M, et al. Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab[J]. South Med J, 2020, 113(11): 600-605. DOI: 10.14423/SMJ.0000000000001166. doi: 10.14423/SMJ.0000000000001166 pmid: 33140115
[17]	Chen X, Sheikh K, Nakajima E, et al. Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies[J]. Oncologist, 2021, 26(10): e1822-e1832. DOI: 10.1002/onco.13900. doi: 10.1002/onco.13900
[18]	Liu Y, Wang W, Shiue K, et al. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer[J]. Radiother Oncol, 2021, 156: 231-238. DOI: 10.1016/j.radonc.2020.10.015. doi: 10.1016/j.radonc.2020.10.015
[19]	Shintani T, Kishi N, Matsuo Y, et al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab[J]. Clin Lung Cancer, 2021, 22(5): 401-410. DOI: 10.1016/j.cllc.2021.01.017. doi: 10.1016/j.cllc.2021.01.017 pmid: 33678582
[20]	Teng F, Li M, Yu J. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications[J]. BMC Med, 2020, 18(1): 275. DOI: 10.1186/s12916-020-01718-3. doi: 10.1186/s12916-020-01718-3 pmid: 32943072
[21]	Teng F, Meng X, Kong L, et al. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review[J]. Cancer Lett, 2018, 414: 166-173. DOI: 10.1016/j.canlet.2017.11.014. doi: S0304-3835(17)30732-2 pmid: 29155348
[22]	Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, et al. Radia-tion-induced lung injury: current evidence[J]. BMC Pulm Med, 2021, 21(1): 9. DOI: 10.1186/s12890-020-01376-4. doi: 10.1186/s12890-020-01376-4 pmid: 33407290
[23]	Riemann D, Cwikowski M, Turzer S, et al. Blood immune cell biomarkers in lung cancer[J]. Clin Exp Immunol, 2019, 195(2): 179-189. DOI: 10.1111/cei.13219. doi: 10.1111/cei.13219 pmid: 30246868
[24]	符伶俐, 李萍, 张芮, 等. 胸部肿瘤患者辐射性肺炎的发生和预测因素[J]. 国际肿瘤学杂志, 2020, 47(2): 107-111. DOI: 10.3760/cma.j.issn.1673-422X.2020.02.009. doi: 10.3760/cma.j.issn.1673-422X.2020.02.009
[25]	王慧, 夏茸, 魏清雯, 等. 非小细胞肺癌免疫检查点抑制剂相关性肺炎的危险因素及预测生物标志物[J]. 国际肿瘤学杂志, 2021, 48(5): 296-301. DOI: 10.3760/cma.j.cn371439-20210115-00057. doi: 10.3760/cma.j.cn371439-20210115-00057
[26]	Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125: 150-156. DOI: 10.1016/j.lungcan.2018.09.015. doi: S0169-5002(18)30574-9 pmid: 30429014
[27]	Gomatou G, Tzilas V, Kotteas E, et al. Immune checkpoint inhibitor-related pneumonitis[J]. Respiration, 2020, 99(11): 932-942. DOI: 10.1159/000509941. doi: 10.1159/000509941 pmid: 33260191
[28]	Riviere P, Sumner W, Cornell M, et al. Radiation recall pneumonitis after treatment with checkpoint blockade immunotherapy: a case series and review of literature[J]. Front Oncol, 2021, 11: 662954. DOI: 10.3389/fonc.2021.662954. doi: 10.3389/fonc.2021.662954
[29]	Nakamura K, Okubo K, Takahashi T, et al. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma[J]. IJU Case Rep, 2019, 2(1): 30-33. DOI: 10.1002/iju5.12032. doi: 10.1002/iju5.12032
[30]	Shaverdian N, Thor M, Shepherd AF, et al. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab[J]. Cancer Med, 2020, 9(13): 4622-4631. DOI: 10.1002/cam4.3113. doi: 10.1002/cam4.3113
[31]	Saito G, Oya Y, Taniguchi Y, et al. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)[J]. Lung Cancer, 2021, 161: 86-93. DOI: 10.1016/j.lungcan.2021.08.019. doi: 10.1016/j.lungcan.2021.08.019 pmid: 34543942

免疫检查点抑制剂引发放射唤醒性肺炎的研究进展

Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[4]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[5]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[6]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[7]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[8]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[11]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[12]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[13]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[14]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[15]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.